Avant Diagnostics Inc fka AVDX

[MikeCr]

Avant Diagnostics to Present at LD Micro
PR Newswire

WASHINGTON, June 1, 2018

WASHINGTON, June 1, 2018 /PRNewswire/ -- Avant Diagnostics, Inc. (OTC:AVDX) (the "Company," or AVDX), a healthcare data generating technology company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology, today announced that its new President & CEO, Mick Ruxin, M.D., will be presenting a corporate overview at the 8th Annual LD Micro Invitational on June 5th, 2018 at 2:00pm PT. Management will be available to meet with interested parties for one-on-one meetings throughout the event.

Presentation Details

Event: 8th Annual LD Micro Invitation
Date: Tuesday, June 5, 2018
Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
Location: Luxe Sunset Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049
Website: https://www.ldmicro.com/events

About Avant Diagnostics, Inc.
Avant Diagnostics, Inc. (Avant) is a healthcare data generating technology company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology. Avant provides personalized medicine data through its TheraLink® assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders, for over 70 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across multiple cancer types, including breast, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Theralink®, was developed to empower community physicians and clinical trial investigators with actionable information to make time sensitive treatment decisions for their patients. Theralink® was designed to inform physicians which treatments are likely to be effective for their patients at any given moment in time, and also identify which treatments are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.

Avant Diagnostics' Pharma Services Business will help drug companies accelerate their drug discovery programs and facilitate development of companion diagnostics. Avant's data generating technologies will also:

Stratify subjects entering clinical trials (reduces trial costs with smaller cohorts)
Monitor on and off target drug effects (regulatory filings)
Quantify phosphoproteome to identify activation of resistance or compensatory pathways post-treatment
Evaluate potential proteomic markers for combination therapies
Repurpose existing therapies for new indications (off-patent drugs and market expansion)
For further information please visit www.Avantdiagnostics.com.